Genedata, a leading provider of in-silico solutions for pharmaceutical R&D and related life sciences, today announced the expansion of its 10 year research informatics partnership with Bayer HealthCare to include all of Bayer Schering Pharma (BSP) drug discovery research sites. Genedata will provide its enterprise software platforms for research data integration and analysis across the Bayer Schering Pharma sites globally to help consolidate and harmonize the drug discovery process.
“Our scalable and open enterprise software platforms are perfectly suited to integrating a variety of drug discovery related data across multiple locations, functions and projects,” said Dr. Othmar Pfannes, CEO of Genedata. “We are pleased to be able to expand our collaboration by providing research informatics systems that ease the information consolidation process of disparate datasets and systems.”
The Genedata collaboration with Bayer Schering Pharma includes the provision and the tailoring of Genedata’s Expressionist® and Phylosopher® platforms to support BSP’s research processes. In addition, Genedata will provide professional services to support integration and to provide interfaces to existing research logistics infrastructure including laboratory technologies and related IT systems.
Genedata Phylosopher® is used for consolidating portfolios of therapeutic targets and for managing the increasing complexity of biological target information. By integrating targets with proprietary compound information, patent information, disease pathways and information on experimental evidences indicating impact on relevant medical indications, Phylosopher represents the central target database that connects the different research groups on a global scale within BSP.
Genedata Expressionist® is used for high throughput processing and quality control of raw gene expression data as well as for statistical analysis to identify differentially expressed genes for target candidate identification, compound profiling, and mode of action studies. Genedata Phylosopher® is subsequently used to evaluate and prioritize target candidates.
Genedata (genedata.com) develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata’s solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high-throughput technologies. Our solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston & San Francisco, USA, Konstanz & Munich, Germany and Tokyo, Japan.